Online inquiry

IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15474MR)

This product GTTS-WQ15474MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15474MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12390MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ4663MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ755MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ6618MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ11698MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ14761MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ5316MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ3075MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW